Previous Close | 8.43 |
Open | 8.24 |
Bid | 8.31 x 1400 |
Ask | 8.30 x 800 |
Day's Range | 7.50 - 8.49 |
52 Week Range | 2.60 - 15.00 |
Volume | 778,266 |
Avg. Volume | 1,323,214 |
Market Cap | 491.362M |
Beta (5Y Monthly) | 2.04 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.80 |
Earnings Date | Mar 09, 2021 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 19.50 |
Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, announced today that company management will participate in two upcoming investor conferences in March:
Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced that the company will host a conference call and live audio webcast on Tuesday, March 9, 2021, at 8:30 a.m. ET to review its full year 2020 financial results and provide an update on the company.
Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today announced that results from the Phase 3 clinical trial of omidubicel will be presented in an oral session at the Presidential Symposium of the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT 2021), which is being held virtually March 14–17, 2021.